Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda R&D Day Explores Pipeline Opportunities

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.

You may also be interested in...

New Anti-Epileptic Drug Formulations Try To Overcome Tolerability Problems

Much of the drug development activity in epilepsy is focused on improving the existing treatments.

Acorda Expands Pipeline With Neuronex And New Ampyra Indications

Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.

Acorda Builds Ampyra Promotion On Years Of MS Outreach

Acorda's challenge in marketing its multiple sclerosis drug Ampyra is not that it is a new drug, but that it is a new drug indicated to treat an aspect of the disease that has never before been treated


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts